Feasibility study on the MammoSite in early‐stage breast cancer: Initial experience

Abstract

The aims of this study were to evaluate the feasibility, practicality, efficacy and safety of the delivery of accelerated partial breast irradiation using the MammoSite for the boost phase. Six patients aged 53-69 years with stage T1N0, T2N0, Grade I-II invasive ductal carcinoma received 9-10 Gy prescribed at 1 cm from the MammoSite balloon surface in two fractions of 4.5-5 Gy 6 h apart. The MammoSite was inserted 20-37 days postoperatively. External beam radiation therapy to the whole breast commenced 1-5 days after accelerated partial breast irradiation. The maximum skin dose ranged from 3 to 9 Gy. The skin-cavity distance ranged from 7 to 19 mm. Local discomfort resolved as the scar healed spontaneously within 3-5 days. No Grade III or higher acute toxicity or local infection was recorded. The ease of insertion and accuracy of dosimetry makes the MammoSite suitable for use in properly selected women with early-stage breast cancer in a trial setting.

Investigation of source position uncertainties & balloon deformation in MammoSite brachytherapy on treatment effectiveness

“…The balloon was then deformed by up to 4 mm in 1 mm steps and similarly 3.4 Gy was delivered at the prescription point. The deformation margin was chosen since typical treatment protocols allow 4 mm balloon deformation [16]. Dose volume histograms were constructed for each deformation treatment plan.…”

Novel Strategies in Lymphedema

“…In addition, radiation exposure is associated with trauma to the lymphatic system, and current standard of care includes BCS and SLNB together with radiation therapy to breast and /or axilla. Recent innovative approaches to radiotherapy include the single-day targeted intraoperative radiotherapy delivered by the Targit machine (Enderling, Anderson, Chaplain, Munro, & Vaidya, 2006;Vaidya et al, 2006) and the 5-day accelerated partial breast irradiation using a MammoSite catheter (Benitez, et al 2006;Berlin, Gjores, Ivarsson, Palmqvist, Thagg, & Thulesius, 1999;Borg et al, 2007;Dragun, Harper, Jenrette, Sinha, & Cole, 2007;Jeruss et al, 2006). Such novel radiotherapies targeting directly on the tumor site while avoiding scattering radiation to the axilla may have a role in reducing the risk of lymphedema in comparison to conventional radiotherapy.…”

Preparing for and Coping with Breast Cancer-Related Lymphedema

“…Recent innovative approaches to radiotherapy include the single-day targeted intraoperative radiotherapy delivered by the Targit machine (Enderling, Anderson, Chaplain, Munro, & Vaidya, 2006;Vaidya et al, 2006) and the 5-day accelerated partial breast irradiation using a MammoSite catheter (Benitez, et al 2006;Berlin, Gjores, Ivarsson, Palmqvist, Thagg, & Thulesius, 1999;Borg et al, 2007;Dragun, Harper, Jenrette, Sinha, & Cole, 2007;Jeruss et al, 2006). Such novel radiotherapies targeting directly on the tumor site while avoiding scattering radiation to the axilla may have a role in reducing the risk of lymphedema in comparison to conventional radiotherapy.…”